Literature DB >> 25802280

Loss of Androgen-Regulated MicroRNA 1 Activates SRC and Promotes Prostate Cancer Bone Metastasis.

Yen-Nien Liu1, JuanJuan Yin2, Ben Barrett2, Heather Sheppard-Tillman2, Dongmei Li3, Orla M Casey2, Lei Fang2, Paul G Hynes2, Amir H Ameri2, Kathleen Kelly4.   

Abstract

Bone metastasis is the hallmark of progressive and castration-resistant prostate cancers. MicroRNA 1 (miR-1) levels are decreased in clinical samples of primary prostate cancer and further reduced in metastases. SRC has been implicated as a critical factor in bone metastasis, and here we show that SRC is a direct target of miR-1. In prostate cancer patient samples, miR-1 levels are inversely correlated with SRC expression and a SRC-dependent gene signature. Ectopic miR-1 expression inhibited extracellular signal-regulated kinase (ERK) signaling and bone metastasis in a xenograft model. In contrast, SRC overexpression was sufficient to reconstitute bone metastasis and ERK signaling in cells expressing high levels of miR-1. Androgen receptor (AR) activity, defined by an AR output signature, is low in a portion of castration-resistant prostate cancer. We show that AR binds to the miR-1-2 regulatory region and regulates miR-1 transcription. Patients with low miR-1 levels displayed correlated low canonical AR gene signatures. Our data support the existence of an AR-miR-1-SRC regulatory network. We propose that loss of miR-1 is one mechanistic link between low canonical AR output and SRC-promoted metastatic phenotypes.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25802280      PMCID: PMC4420926          DOI: 10.1128/MCB.00008-15

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  46 in total

1.  Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators.

Authors:  Haley Hieronymus; Justin Lamb; Kenneth N Ross; Xiao P Peng; Cristina Clement; Anna Rodina; Maria Nieto; Jinyan Du; Kimberly Stegmaier; Srilakshmi M Raj; Katherine N Maloney; Jon Clardy; William C Hahn; Gabriela Chiosis; Todd R Golub
Journal:  Cancer Cell       Date:  2006-09-28       Impact factor: 31.743

2.  Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth.

Authors:  David J Mulholland; Linh M Tran; Yunfeng Li; Houjian Cai; Ashkan Morim; Shunyou Wang; Seema Plaisier; Isla P Garraway; Jiaoti Huang; Thomas G Graeber; Hong Wu
Journal:  Cancer Cell       Date:  2011-05-27       Impact factor: 31.743

3.  Lentivirus-mediated bifunctional cell labeling for in vivo melanoma study.

Authors:  Chi-Ping Day; John Carter; Carrie Bonomi; Dominic Esposito; Bruce Crise; Betty Ortiz-Conde; Melinda Hollingshead; Glenn Merlino
Journal:  Pigment Cell Melanoma Res       Date:  2009-01-19       Impact factor: 4.693

4.  SRC family kinase activity is up-regulated in hormone-refractory prostate cancer.

Authors:  Oleg Tatarov; Thomas J Mitchell; Morag Seywright; Hing Y Leung; Valerie G Brunton; Joanne Edwards
Journal:  Clin Cancer Res       Date:  2009-05-15       Impact factor: 12.531

Review 5.  Functional role of microRNAs in prostate cancer and therapeutic opportunities.

Authors:  Marcello Maugeri-Sacca; Valeria Coppola; Ruggero De Maria; Desiree Bonci
Journal:  Crit Rev Oncog       Date:  2013

Review 6.  New and emerging therapies for bone metastases in genitourinary cancers.

Authors:  Philip J Saylor; Andrew J Armstrong; Karim Fizazi; Stephen Freedland; Fred Saad; Matthew R Smith; Bertrand Tombal; Kenneth Pienta
Journal:  Eur Urol       Date:  2012-11-23       Impact factor: 20.096

7.  Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone.

Authors:  Martine P Roudier; Lawrence D True; Celestia S Higano; Hubert Vesselle; William Ellis; Paul Lange; Robert L Vessella
Journal:  Hum Pathol       Date:  2003-07       Impact factor: 3.466

8.  Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.

Authors:  Qianben Wang; Wei Li; Yong Zhang; Xin Yuan; Kexin Xu; Jindan Yu; Zhong Chen; Rameen Beroukhim; Hongyun Wang; Mathieu Lupien; Tao Wu; Meredith M Regan; Clifford A Meyer; Jason S Carroll; Arjun Kumar Manrai; Olli A Jänne; Steven P Balk; Rohit Mehra; Bo Han; Arul M Chinnaiyan; Mark A Rubin; Lawrence True; Michelangelo Fiorentino; Christopher Fiore; Massimo Loda; Philip W Kantoff; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

9.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

10.  MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer.

Authors:  Robert S Hudson; Ming Yi; Dominic Esposito; Stephanie K Watkins; Arthur A Hurwitz; Harris G Yfantis; Dong H Lee; James F Borin; Michael J Naslund; Richard B Alexander; Tiffany H Dorsey; Robert M Stephens; Carlo M Croce; Stefan Ambs
Journal:  Nucleic Acids Res       Date:  2011-12-30       Impact factor: 16.971

View more
  29 in total

Review 1.  MicroRNAs in prostate cancer: From function to biomarker discovery.

Authors:  Ahmed A Moustafa; Hogyoung Kim; Rasha S Albeltagy; Ola H El-Habit; Asim B Abdel-Mageed
Journal:  Exp Biol Med (Maywood)       Date:  2018-06

Review 2.  The Functional Role of Prostate Cancer Metastasis-related Micro-RNAs.

Authors:  Ulrich H Weidle; Alexandra Epp; Fabian Birzele; Ulrich Brinkmann
Journal:  Cancer Genomics Proteomics       Date:  2019 Jan-Feb       Impact factor: 4.069

3.  Micro-RNA-1 is decreased by hypoxia and contributes to the development of pulmonary vascular remodeling via regulation of sphingosine kinase 1.

Authors:  Justin R Sysol; Jiwang Chen; Sunit Singla; Shuangping Zhao; Suzy Comhair; Viswanathan Natarajan; Roberto F Machado
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-11-22       Impact factor: 5.464

4.  Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis.

Authors:  W-Y Chen; Y-C Tsai; M K Siu; H-L Yeh; C-L Chen; J J Yin; J Huang; Y-N Liu
Journal:  Oncogene       Date:  2017-07-10       Impact factor: 9.867

5.  EGF Receptor Promotes Prostate Cancer Bone Metastasis by Downregulating miR-1 and Activating TWIST1.

Authors:  Yung-Sheng Chang; Wei-Yu Chen; Juan Juan Yin; Heather Sheppard-Tillman; Jiaoti Huang; Yen-Nien Liu
Journal:  Cancer Res       Date:  2015-06-12       Impact factor: 12.701

6.  Platelets Promote Metastasis via Binding Tumor CD97 Leading to Bidirectional Signaling that Coordinates Transendothelial Migration.

Authors:  Yvona Ward; Ross Lake; Farhoud Faraji; Jamie Sperger; Philip Martin; Cameron Gilliard; Kimberly P Ku; Tamara Rodems; David Niles; Heather Tillman; JuanJuan Yin; Kent Hunter; Adam G Sowalsky; Joshua Lang; Kathleen Kelly
Journal:  Cell Rep       Date:  2018-04-17       Impact factor: 9.423

7.  TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.

Authors:  M K Siu; W-Y Chen; H-Y Tsai; H-Y Chen; J J Yin; C-L Chen; Y-C Tsai; Y-N Liu
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-02-21       Impact factor: 5.554

Review 8.  MicroRNA Exert Macro Effects on Cancer Bone Metastasis.

Authors:  Scott R Baier; Yihong Wan
Journal:  Curr Osteoporos Rep       Date:  2016-10       Impact factor: 5.096

Review 9.  Dissecting the role of microRNAs in prostate cancer metastasis: implications for the design of novel therapeutic approaches.

Authors:  Valentina Doldi; Marzia Pennati; Barbara Forte; Paolo Gandellini; Nadia Zaffaroni
Journal:  Cell Mol Life Sci       Date:  2016-03-12       Impact factor: 9.261

10.  MiR-381 inhibits epithelial ovarian cancer malignancy via YY1 suppression.

Authors:  Bairong Xia; Huiyan Li; Shanshan Yang; Tianbo Liu; Ge Lou
Journal:  Tumour Biol       Date:  2016-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.